InVivo names new CEO
This article was originally published in Clinica
Cambridge, Massachusetts-based InVivo Therapeutics has named Mark Perrin chief executive officer – effective 6 January 2014. Upon his appointment, Mr Perrin will also become a member of the company's board of directors. Prior to joining the company – which specializes in drug delivery technologies for spinal cord injuries – Mr Perrin was president of Dennan Consulting, a biotech consulting firm. Mr Perrin replaces interim CEO Michael Astrue, who has been filling in since previous leader Francis Reynold stepped down in August due to a medical condition. Meanwhile, InVivo has also promoted Lisa Crockett to vice-president, regulatory and Kristin Neff to vice-president, clinical operations, effective 1 January 2014. The firm also recently made Steven McAllister interim CEO, making him the third person to head up its finance division in the last three months. InVivo saw its share price plunge in August after delaying its first-in-human trials of its biopolymer scaffold.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.